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Cerebral artery dilatation maintains cerebral
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hypoxia—an ultrasound and MRI study
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Transcranial Doppler is a widely used noninvasive technique for assessing cerebral artery blood
flow. All previous high altitude studies assessing cerebral blood flow (CBF) in the field that have
used Doppler to measure arterial blood velocity have assumed vessel diameter to not alter. Here, we
report two studies that demonstrate this is not the case. First, we report the highest recorded study
of CBF (7,950m on Everest) and demonstrate that above 5,300m, middle cerebral artery (MCA)
diameter increases (n=24 at 5,300m, 14 at 6,400m, and 5 at 7,950m). Mean MCA diameter at sea
level was 5.30mm, at 5,300m was 5.23mm, at 6,400m was 6.66mm, and at 7,950m was 9.34mm
(P<0.001 for change between 5,300 and 7,950m). The dilatation at 7,950m reversed with oxygen.
Second, we confirm this dilatation by demonstrating the same effect (and correlating it with
ultrasound) during hypoxia (FiO2=12% for 3 hours) in a 3-T magnetic resonance imaging study at
sea level (n=7). From these results, we conclude that it cannot be assumed that cerebral artery
diameter is constant, especially during alterations of inspired oxygen partial pressure, and that
transcranial 2D ultrasound is a technique that can be used at the bedside or in the remote setting to
assess MCA caliber.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 8 June 2011; doi:10.1038/jcbfm.2011.81
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Introduction
Normal cerebral function is dependent on an
adequate and continuous supply of oxygen. With
increasing altitude, barometric pressure falls, and
with it the partial pressure of atmospheric and
inspired oxygen. Acclimatization to such an
environmental hypobaric hypoxic stress involves a
number of adaptive processes (including hyper-
ventilation and a rise in hematocrit (Ward et al,
2000)), which serve to restore arterial oxygen content
toward sea level values. In addition, increased
cerebral blood flow (CBF) is believed to be one
compensatory mechanism serving to maintain nor-
mal oxygen flux to the brain in the face of arterial
hypoxemia. Such hypoxemia is common in critically
ill patients and is thought to occur locally in
ischemic stroke, the third commonest cause of death
in the United Kingdom (The National Institute of
Neurological Disorders and Stroke rt-PA Stroke
Study Group, 1995). A greater understanding of the
cerebrovascular response to hypoxia is thus of broad
interest, as would be the validation of clinically
relevant techniques to assess flow in intracranial
vessels.
Transcranial Doppler (TCD) measurement of flow
velocity in the middle cerebral artery (MCA) has
been used to assess CBF dynamics both at rest and
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during exercise at altitude (Ainslie et al, 2007;
Appenzeller et al, 2004; Baumgartner et al, 1994,
1999; Feddersen et al, 2007; Imray et al,
2005; Jansen et al, 2000, 2002; Lysakowski et al,
2004; Norcliffe et al, 2005; Otis et al, 1989; Palma
et al, 2006; Subudhi et al, 2007; Ter Minassian et al,
2001; Van Osta et al, 2005). Assuming cerebral
arterial diameter remains constant in the face of
sustained hypoxia, investigators have inferred
changes in CBF from changes in the velocity of
blood in the MCA. This assumption is, however,
disputed (Giller, 2003). Further, an opposite (contra-
dictory) assumption is made in many clinical
situations: in the management of subarachnoid
hemorrhage, for example, changes in TCD-derived
blood velocity are assumed to represent changes in
vessel diameter (vasospasm).
The profound hypoxemia experienced by climbers
at extreme altitude ( > 5,500m) (Grocott et al, 2009) is
known to be associated with cerebral dysfunction
(Virues-Ortega et al, 2004; Ward et al, 2000),
identified in B70% of deaths over 8,000m on
Everest (Firth et al, 2008). Such data suggest that
cerebral oxygenation may not be fully maintained
through adaptive responses, which may include
changes in CBF. However, these blood flow re-
sponses remain poorly documented. Indeed, the
only studies of CBF using TCD velocity under
conditions of comparable hypoxemia have been
performed in a hypobaric chamber and vessel
diameter was not measured (Ter Minassian et al,
2001).
In the past, the measurement of MCA diameter
(MCADiam) has only been possible by direct vision at
surgery (Giller et al, 1993), by use of contrast
angiography (Du Boulay and Symon, 1971) or
magnetic resonance angiography (MRA)—techniques
inappropriate for remote extreme altitude field
studies. Transcranial color Doppler power signal
has previously been used to indirectly infer MCA
crosssectional area in a laboratory setting (Poulin and
Robbins, 1996). Under conditions of mild hypobaric
hypoxia, no significant change in MCA crosssec-
tional area was noted. The recent development of
portable ultrasound devices that incorporate both 2D
color flow mapping and concurrent pulse wave
Doppler ultrasonography permits measurement of
both vessel diameter and the velocity of the blood
within it. The 2D ultrasound ensures that the same
segment of the artery can be reliably visualized and
assessed.
We thus aimed to use such ultrasound imaging and
Doppler measurements to characterize the contribu-
tion of altered vessel diameter to changes in MCA
flow (MCAFlow) and calculated oxygen delivery
(MCAOD) seen in response to hypobaric hypoxia. In
addition, a sea level MRA study was performed in
normoxia and 12% hypoxia to determine whether
acute hypoxia caused MCA vessel dilatation and to
explore correlation between TCD and MRA meth-
odologies.
Materials and methods
Ethical approval for this study was provided by University
College London (Code 0292/015). Written informed con-
sent was obtained from all participants.
High Altitude Transcranial Doppler Study
Twenty-four subjects (18 males, mean age: 35.2 years, range:
19 to 59 years) of the Caudwell Xtreme Everest Research
Expedition (described with ascent profile elsewhere (Gro-
cott et al, 2010) were studied over 71 days. All subjects
trekked to 5,300m (group 1, n=24), of whom 14 subse-
quently continued to 6,400m (group 2) and 5 to 7,950m
(group 3). Each subject was studied between 1 and 3 days
after arrival at each altitude. The study day was constant for
each subject, the sole exception being at 7,950m, where all
subjects (n=5) were investigated on the second day after
arrival. No caffeine, alcohol, or medication that could affect
CBF was consumed before the measurement on the study
day. Immediately before each study, subjects rested in a
horizontal position for 15minutes. Climbers were not
exposed to any supplemental oxygen until 7,100m. At
7,950m, subjects were off supplementary oxygen (2L/min)
for at least 30minutes before the near infrared spectroscopy
(NIRS) and TCD measurements were made. The NIRS and
TCD studies were then repeated with the subjects receiving
2L/min supplemental oxygen via a TopOut rebreath
regulator system (Topout Mask Mk 2, Topout Oxygeneering
Ltd, Cotgrave, UK) to assess reversibility of the initial
measurements. At 7,950m, the investigating clinician
(CHEI) used supplementary oxygen (2L/min).
Measurements
Blood pressure was recorded (mean of three noninvasive
recordings) using an automated cuff (Omron M7, Bannock-
burn, IL, USA); arterial oxygen saturation (SaO2) by near
infrared finger pulse oximetry probe (Nonin, Onyx Model
9500, Plymouth, MN USA); hemoglobin concentration of
whole venous blood by photometry (Hemocue Whole
Blood hemoglobin System, Hemocue AB, Angelhoim,
Sweden); and resting end tidal CO2 (ETCO2) by infrared
capnometer (Cortex Metamax 3b, Leipzig, Germany).
Near infrared spectroscopy: Regional brain oxygen
saturation (rSO2) measurements were made immediately
before TCD insonation (Invos Cerebral Oximeter 5100C,
Somanetics, Troy, MI, USA). The skin was cleaned and
probes were placed over the right and left frontal lobes
avoiding both the sagittal and frontal sinuses, and left in situ
during the TCD analysis. Three consecutive readings were
taken from each side, from which means were calculated.
Transcranial Doppler: In a supine subject, the right MCA
was insonated via the temporal bone window, by one of the
two skilled observers, using a 5 to 1MHz Transducer
MicroMaxx (Sonosite, Bothell, WA, USA). The clinoid
process of the sphenoid bone, the Circle of Willis, and the
distal internal carotid artery were initially identified,
and then the M1 segment of the MCA was identified
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(characterized by flow toward the transducer). Doppler gain
was set in a standard manner (Martinoli and Derchi, 1997).
An optimal portion of the MCAwithout branches and with
near laminar flow was then selected and the depth
recorded. Once identified, the center of the artery was
insonated and MCA blood velocity (MCAVel), peak systolic
velocity, end diastolic velocity, pulsatility index (the
difference between peak systolic and minimum diastolic
flow velocities divided by the mean flow velocity; which
in certain circumstances reflects intracranial pressure),
and resistivity index (the difference between peak systolic
and minimum diastolic flow velocities divided by the
peak systolic velocity) were calculated by the inbuilt
software (Figure 1A). On subsequent studies, every effort
was made to insonate the same depth (to within 1mm).
After 3 to 5minutes of insonation, the 2D image movie
sequence was saved, and the frame with the maximum
vessel diameter (systole) studied. Using the on-screen
caliper tool, the width of the vessel at the point of
insonation was measured and recorded (Figure 1B). The
angle of insonation was constant for each individual, since
the position of the probe on the temporal bone window
and the position on the interrogated section of the MCA
were fixed.
Sea Level Hypoxic Magnetic Resonance Imaging Study
Seven subjects (5 males; mean age: 34.4 years, range: 22 to
48 years) were recruited from the Caudwell Xtreme Everest
investigators. None had ascended above 1,000m in the
preceding 6 months. Physiological, TCD, and NIRS
measurement techniques were identical to the field study
and performed in normoxia, at 90 and 180minutes of
hypoxia. All TCD measurements were performed three
times by both investigators.
Hypoxia: After baseline measurements, subjects were
subjected to 3hours of normobaric hypoxia (FiO2=12%;
approximately equivalent to an altitude of 4,400m), using a
tight fitting mask and hypoxicator (Everest Summit
Hypoxic Generator, Hypoxic Systems, New York, NY,
USA). Inspired oxygen concentration was regularly
checked (Class R-17D Oxygen Sensor, Oxycheq, Marianna,
FL, USA). Extended magnetic resonance imaging (MRI)-
compatible tubing enabled the subjects to remain hypoxic
during the MRI and TCD studies at 3hours.
Magnetic Resonance Imaging: A 3-T MRI (TIM Trio,
Siemens AG, Eriangen, Germany) was performed at baseline
and at 3hours of hypoxia. At both time points 3D time of
flight MRA was performed (repetition time (TR)=8.6milli-
seconds; echo time (TE)=4milliseconds; flip angle
(FA)=201; three acquisition slabs; matrix 256 256 15;
voxel dimensions 1.2 1.0 7.0mm3), principally to permit
estimation of MCADiam. To measure MCA blood flow
velocity, a single-slice 2D electrocardiogram-triggered seg-
mented phase-contrast acquisition (TR=30.3milliseconds;
TE=5.5milliseconds; FA=301; matrix 384 384; voxel
dimensions 0.5 0.5 6.0mm3) was performed with
through-plane flow sensitization with velocity-encoding
factor of 150 cm/s. An 800-milliseconds electrocardio-
gram-synchronized acquisition window was sampled
with 25 phases proving velocity sensitive images with
an effective temporal resolution of 32milliseconds.
Figure 1 Ultrasound images demonstrating (A) velocity/ratio and (B) vessel diameter measurement and (C) composite of four
magnetic resonance imaging (MRI) images, demonstrating middle cerebral artery (MCA) multiplanar reconstruction and analysis.
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A consistent section of the right proximal MCA (B1 cm
from the bifurcation to correspond to the TCD area of
investigation) was studied to provide estimates of blood
velocity, the imaging plane being prescribed orthogonally
to the main axis of the MCA.
To estimate MCADiam, time of flight MRA data were
postprocessed using the maximum intensity projection
function on a calibrated Siemens Leonardo workstation
(Siemens AG). An independent consultant neuroradiolo-
gist, blinded to the pre- or post-hypoxia-induced status of
the subjects, assessed the maximum and minimum
diameters, the circumference and crosssectional area of
both MCAs on two data sets in all subjects. A semiauto-
mated vessel tracing technique utilizing the In-Space
vessel analysis program (Syngo MMWP Software, version
VE36A with service pack SP03, Siemens, Munich,
Germany) was performed to analyze the length of MCA
on the postprocessed 3D rendered maximum intensity
projection images. This was performed by manually
entering two data points; proximally at the A1/M1
bifurcation of the terminal internal carotid artery and
distally at the distal M1 segment of the MCA at the bi/
trifurcation. Multiplanar views of the segmented length for
analysis of the M1 segment were then automatically
generated by the program, which included a true cross-
sectional view (Figure 1C). This automatically generated
length of the M1 segment of the MCA was then divided
equally into five data points, these data points were
replicated and were therefore consistent in both the studies
(pre- and post-hypoxia) for the respective lateralized M1
segment. The window width and level were standardized
on the true crosssectional display panel at 200:100. A
semiautomated calculation of the crosssectional area and
circumference was performed by the program using a ‘best-
fit’ algorithm with minimal refinement of the threshold
levels and individual plotted data points. The maximum
and minimum diameters were also determined at the same
data point. This process was repeated at all five data points
for each side (left and right M1 segments) in pre- and post-
hypoxia-induced studies in all patients. Similar vessel
analysis techniques have been previously utilized by other
researchers to interrogate time of flight MRA acquisitions
(Beckmann, 2000; Besselmann et al, 2001; Choy et al, 2006;
Reese et al, 1999).
Middle cerebral artery flow velocities were obtained
from the phase-contrast imaging data also using software
provided by Siemens (Argus Flow tool, Siemens, Munich,
Germany). The extent of the MCA margins were deter-
mined by manually defining an enclosing region of
interest, which was adjusted for each phase to account
for changes through the cardiac cycle. The software then
automatically determined the average flow velocity for
each subject.
Flow and oxygen delivery calculations: Blood oxygen
content was calculated using the formula: Blood oxygen
content = 1.36HbSaO2/100. The small quantity of
dissolved oxygen (decreasing further at altitude) was not
included in the estimation.
Middle cerebral artery blood flow was calculated using
the formula: Flow=p(MCAdiam/2)
2
MCAvel. This estimation
does not take account of vessel wall resistance or changes
due to any turbulent flow. Oxygen delivery was calculated
as the product of blood flow and oxygen content.
Statistics
High altitude study: For each measure, differences in
scores between altitudes were examined using the linear
mixed models procedure in SPSS version 18 (IBM, NY,
USA) to maximize the utilization of the data collected. The
method of restricted maximum likelihood was used to
estimate model parameters, and variance/covariance struc-
tures were modeled as heterogeneous Toeplitz. Pairwise
comparisons within each analysis were conducted using
estimated marginal means using Sidak’s adjustment to
compensate for multiple comparisons. For all tests,
significance was set to < 0.05.
Sea level hypoxic magnetic resonance imaging study:
Differences were again examined using the linear mixed
models procedure in SPSS for consistency. The same
means and the same variables were found to reach
significance when checked with general linear models.
Relationships between variables were examined using
Pearson’s correlation. Correlations were considered sig-
nificant when P<0.05. The coefficient of determination (r2)
is also reported as an indicator of the correlation effect size.
Interrater reproducibility for the MRI/TCD ratings was
examined using intraclass correlations (averaged mea-
sures) to examine the agreement between raters over the
range of measures taken at different time points.
Results
High Altitude Transcranial Doppler Study
There were no technical problems encountered with
the TCD and NIRS devices. Data were not available
on one subject at 3,500m (nonaltitude-related gastro-
intestinal disturbance) and one subject at 5,300m
(severe acute mountain sickness). These missing data
were accounted for as part of the multilevel modeling
technique. Subject characteristics and basic physio-
logical variables for the different groups at each
altitude are presented in Table 1.
Table 2 summarizes the means of measured
variables, the confidence intervals, and the signifi-
cance of changes with increasing altitude.
Regional cerebral oxygenation (rSO2) values (de-
rived from NIRS), peripheral saturations (SaO2), and
EtCO2 decreased with each increase in altitude
(P<0.05). MCAvel did not change at any altitude.
The MCADiam remained constant until extreme alti-
tude (6,400 and 7,950m), where a marked increase
was observed (5.3mm at sea level, 6.66mm at 6,400,
and 9.34mm at 7,950m; P<0.002)).
Similarly, calculated MCAFlow and MCAOD mark-
edly increased at 6,400m and above (MCAFlow from
13.3mL/s at sea level to 23.7mL/s and 6,400 and
41.2mL/s at 7,950; oxygen delivery from 2.5mL/s at
Cerebral artery dilatation maintains cerebral oxygenation at altitude
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Table 1 Barometric and subject characteristics plus basic physiological variables with estimated marginal means, significance of change, and confidence intervals (CIs) using
multilevel modeling
75m 1,300m 3,500m 4,250m 5,300m 6,400m 7,950m 7,950m+2L Oxygen Sig
Barometric pressure/kPa 100.5 86.7 67.3 61.5 53.8 46.7 38.9 —
PiO2/kPa 19.7 16.8 12.7 11.6 9.9 8.5 6.8 —
Systolic BP (mmHg) (CI) 129.85a,b (124.21–135.50) 129.25a,b (122.66–135.84) 128.32a (122.42–134.21) 132.89a,b (127.90–137.88) 139.72b (133.45–145.99) 136.03a,b (130.18–141.88) 126.33a,b (108.52–133.14) — 0.047
Diastolic BP (mmHg) (CI) 77.85a (73.86–81.84) 81.25a,c (77.22–85.29) 84.94a,b,c (80.52–89.36) 86.68b,c (83.14–90.23) 90.90b (86.81–95.00) 91.48b (86.67–96.29) 84.96a,b,c (74.08–95.83) — <0.01
Mean BP (mmHg) (CI) 95.18 (91.10–99.26) 97.25 (92.62–101.88) 99.40 (95.09–103.70) 102.08 (98.36–105.80) 107.17 (102.74–111.61) 106.29 (101.56–111.02) 98.76 (85.96–111.56) — 0.003
Peripheral Sats (%) (CI) 97.63a (97.24–98.02) 95.67b (95.01–96.32) 89.75c (88.39–91.11) 85.88d (84.01–87.74) 79.63e (77.68–81.60) 75.13e (72.35–77.91) 65.90f (63.74–68.07) 95.03a,b (92.78–97.27) < 0.001
End tidal CO2 (kPa) (CI) 4.74
a (4.56–4.91) 4.30b (4.13–4.48) 3.65c (3.48–3.81) 3.42d (3.26–3.58) 2.75e (2.61–2.89) 2.23f (2.10–2.37) 1.73 g (1.60–1.87) — <0.001
Hemoglobin (mg/dL) (CI) 13.97 (13.61–14.34) 14.53 (14.20–14.87) 15.43 (14.97–15.89) 15.52 (15.11–15.93) 17.63 (17.00–18.27) 19.09 (17.96–20.23) 18.83 (18.17–19.49) — <0.001
BP, blood pressure.
Note: altitudes with the same superscript letter do not differ significantly (i.e., they belong to a homogenous subset).
Table 2 Estimated marginal means, significance of change, and CIs for each variable using multilevel modeling
75m 1,300m 3,500m 4,250m 5,300m 6,400m 7,950m 7,950m+2L Oxygen Sig
Left rSO2 (%) (CI) 68.77
a (65.91–71.63) 66.00a (64.30–69.70) 62.62b (59.87–65.37) 58.94c (55.89–61.99) 54.16c,d (51.07–57.25) 49.27d (44.84–53.70) 41.95e (39.76–44.15) 62.57a,b,c,e (57.02–68.12) < 0.001
Right rSO2 (%) (CI) 69.47
a (66.74–72.20) 67.75a (64.57–70.93) 61.36b (58.88–63.84) 58.57b,c (55.90–61.24) 53.98c,d (51.11–56.85) 50.95d (47.23–54.67) 39.55e (36.14–42.96) 61.75b (61.42–62.08) < 0.001
Oxygen content
(mLs/100mLs) (CI)
18.55a,b (18.08–19.02) 18.91a (18.44–19.38) 18.83a (18.25–19.41) 18.12a,b (17.54–18.70) 19.02a (18.16–19.89) 19.29a (17.70–20.87) 16.81b (15.87–17.76) 24.27c (23.18–25.37) < 0.001
MCAv (cm/s) (CI) 59.66 (53.25–66.07) 56.08 (51.32–60.84) 62.63 (54.89–70.38) 60.14 (53.22–67.07) 66.97 (59.17–74.76) 66.42 (59.78–73.06) 62.92 (42.73–83.11) 49.03 (27.17–70.88) 0.163
PSV (cm/s) (CI) 91.32 (82.12–100.51) 84.34 (76.89–91.80) 91.73 (82.21–103.24) 92.39 (81.81–102.96) 102.75 (91.74–113.75) 107.10 (96.71–117.48) 96.15 (63.46–128.84) 66.70 (15.68–117.73) 0.116
EDV (cm/s) (CI) 41.25 (36.96–45.55) 40.55 (37.42–43.67) 43.48 (38.34–48.61) 42.98 (37.62–48.35) 48.38 (42.37–54.39) 49.10 (43.45–54.75) 46.42 (26.56–66.28) 37.09 (23.25–50.93) 0.167
Pulsitility index (CI) 0.85 (0.79–0.90) 0.81 (0.76–0.86) 0.78 (0.71–0.84) 0.82 (0.72–0.92) 0.82 (0.75–0.89) 0.87 (0.87–0.97) 0.83 (0.45–1.2) 0.71 (0.50–0.91) 0.213
Resistivity index 0.54 (0.51–0.57) 0.54 (0.52–0.56) 0.52 (0.49–0.55) 0.53 (0.50–0.56) 0.53 (0.50–0.56) 0.54 (0.50–0.57) 0.52 (0.41–0.64) 0.47 (0.37–0.57) 0.410
MCA diameter (mm) 5.30a (5.01–5.59) 5.70a,b (5.38–6.02) 5.51a,c (5.05–5.97) 5.40a (5.07–5.73) 5.23a (4.78–5.68) 6.66b,c,d (6.03–7.30) 9.34b,e (7.62–11.06) 6.0a,d,e (5.03–8.02) 0.003
MCA flow (mL/s) 13.30a (11.38–15.21) 14.54a (12.46–16.61) 15.62a,b (12.53–18.71) 14.42a (11.75–17.09) 15.04a,b (11.74–18.34) 23.68b (18.93–28.43) 41.16a,b (24.51–57.82) 15.27a,b (0.64–29.89) 0.026
Oxygen delivery (mL/s) 2.47a (2.10–2.85) 2.74a,b (2.36–3.11) 2.94a,b (2.34–3.55) 2.61a (2.12–3.10) 2.87a,b (2.25–3.50) 4.69b (3.61–5.78) 6.98a,b (4.25–9.70) 3.68a,b (0.75–8.11) 0.101
CI, confidence interval; EDV, end diastolic velocity; MCA, middle cerebral artery.
Note: altitudes with the same superscript letter do not differ significantly (i.e., they belong to a homogenous subset).
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sea level to 4.7mL/s at 6,400 and 7.0mL/s at 7,950m;
P<0.01 for all). Figure 2 demonstrates these changes
in graphical format.
Sea Level Hypoxic Magnetic Resonance Imaging Study
All seven subjects completed 3hours of hypoxia and
underwent the complete study. Because of technical
difficulties, one observer was unable to adequately
measure the MCAvalues utilizing TCD in one subject
in normoxia. This data set was otherwise complete.
Tables 3 displays the changes in mean blood pressure,
pulse, SO2, rSO2, ETCO2, oxygen content, ultrasound
and MRA-measured vessel diameters, and blood velo-
city and calculated blood flow and oxygen delivery.
Middle cerebral artery diameter increased after 3
hours exposure to 12% hypoxia, when measured
using ultrasound or MRI (TCD: 5.44 to 6.28mm; MRI:
3.04 to 3.27mm; P= <0.05 for both). Cerebral blood
velocity did not significantly increase when assessed
with either method (TCD: 65.2 to 71.6 cm/s; MRI:
32.8 to 38.8 cm/s; P=0.13).
Cerebral blood flow, calculated with either meth-
odology, increased (TCD: 14.8 to 21.9mL/s; MRI: 2.3
to 3.2mL/s; P<0.01).
Calculated oxygen delivery was maintained
whether measured using ultrasound or MRI.
Correlation of Transcranial Doppler and Magnetic
Resonance Imaging
Transcranial Doppler and MRI-measured vessel
diameters correlate (r=0.82 (Pearson’s), r2=0.67
Figure 2 Composite of seven graphs, demonstrating changes in blood pressure, arterial oxygen saturation (SaO2), regional cerebral
oxygenation (rSO2), end tidal CO2 (ETCO2), peak systolic, end diastolic and mean velocities, middle cerebral artery (MCA) diameter
(MCADiam), calculated MCA flow (MCAFlow), and oxygen delivery (note: blood pressure and EtCO2 were not reassessed after oxygen
administration at 7,950m).
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(Figure 3)). However, although there was a strong
correlation, the actual values of diameter appeared to
have a sizeable, though constant, difference between
TCD and MRI, for example, normoxia TCD-measured
MCADiam=5.44mm; normoxia MRA-measured MCA-
Diam=3.04mm. This difference creates marked differ-
ences in calculated flow and oxygen delivery since
the square of the radius has a large contribution to
these calculation (see Discussion).
The interclass correlation between the two TCD
observers was 0.76.
Discussion
This is the first field study to assess cerebral
perfusion over 5,500m. The technical advance
demonstrated in this study is that transcranial
ultrasound can be used to measure changes in
cerebral vessel diameters and the changes detected
using such a technique correlate with MRI measure-
ments. We have shown, for the first time, that
exposure to hypoxia is associated with an increase
in MCADiam and that this is a consistent finding in
both normobaric and hypobaric hypoxia. Thus, the
measurement of velocity alone is likely to be
unreliable in evaluating MCA blood flow. In accli-
matized subjects ascending to extreme altitude, the
vessel caliber change appears to be of greater
importance to increasing flow than changes in the
velocity of the blood within it. Oxygen supplementa-
tion at 7,950m rapidly reversed the observed MCA
vessel dilatation. Such vessel dilatation and its rapid
reversal through administration of supplemental
oxygen have not previously been described, and
challenge currently accepted concepts relating to
adaptive mechanisms.
The main strength of this study is that two
differing techniques (MRA and ultrasound) have
demonstrated that MCADiam increases with hypoxia
and that these techniques are well correlated. We
have demonstrated the same phenomenon in normo-
baric and hypobaric hypoxia and that our findings
are reversed with supplemental oxygen at 7,950m.
However, our studies do have inherent weaknesses,
which relate to subject selection, technical and
logistical limitations. First, subjects were all experi-
enced high altitude climbers, whose physiological
responses may, in some way, have been ‘selected for.’
Table 3 Estimated marginal means, F values, and CIs of heart rate, blood pressure, peripheral and regional brain saturations, end
tidal CO2, calculated oxygen content, transcranial doppler, MRA-measured velocities and ultrasound and MRI-measured diameters,
calculated flows, and calculated oxygen delivery
Normoxia 90minutes Hypoxia 180minutes Hypoxia Sig
Pulse (beats/min) (CI) 58.00 (46.99–69.01) 62.71 (53.39–72.04) 64.14 (55.03–73.26) 0.27
Systolic BP (mmHg) 115.90 (109.32–122.40) 113.86 (105.36–122.36) 114.71 (97.13–132.30) 0.67
Diastolic BP (mmHg) 68.00 (58.95–77.05) 62.86 (59.30–66.42) 66.57 (55.54–77.61) 0.167
SaO2 (%) 98.29
a (96.06–100.51) 76.00b (67.66–84.34) 74.86b (67.55–82.16) < 0.001
rSO2 (mean R&L) (%) 71.10
a (63.58–78.61) 50.47b (45.92–55.03) 50.33b (44.62–56.04) < 0.001
End tidal CO2 (kPa) 5.23
a (4.43–6.03) 2.64b (1.95–3.33) 2.63b (1.97–3.30) < 0.001
Oxygen content (mL per 100mLs) 18.78a (17.84–19.71) 14.57b (12.51–16.63) 14.34b (12.53–16.15) 0.001
TCD-measured MCAv (cm/s) 65.23a (48.36–82.10) 74.29b (55.60–92.98) 71.60a,b (51.51–91.68) 0.004
MRA-measured MCAv (cm/s)y 32.80 (21.61–43.99) — 38.75 (27.25–50.35) 0.006
TCD-measured diameter (mm) 5.44a (5.17–5.70) 6.23b (5.67–6.78) 6.28a,b (5.61–6.95) 0.021
MRA-measured diameter (mean R&L) (mm)y 3.04a (2.79–3.29) — 3.27b (3.01–3.53) 0.006
TCD calculated flow (mL/s) 14.83a (12.34–17.31) 22.07b (18.31–25.84) 21.87b (15.90–27.84) 0.002
MRA calculated flow (mL/s)y 2.33a (16.54–29.98) — 3.23b (22.75–41.76) 0.013
TCD calculated O2 delivery (mLsO2/s) 2.77 (2.38–3.15) 3.18 (2.63–3.74) 3.15 (2.15–4.14) 0.184
MRA Calculated O2 delivery (mLsO2/s)
y 0.44 (0.32–0.55) — 0.45 (0.32–0.59) 0.586
BP, blood pressure; CI, confidence interval; MCA, middle cerebral artery; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; TCD,
Transcranial Doppler.
yNo MRI studies done at 90minutes of hypoxia.
Note: altitudes with the same superscript letter do not differ significantly (i.e., they belong to a homogenous subset).
Figure 3 A graph demonstrating the correlation between
transcranial Doppler (TCD) and magnetic resonance imaging
(MRI) measurements of middle cerebral artery (MCA) diameter.
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Many were young (which may account for some
of the differences in MCADiam compared with
angiographic/cadaver studies—see below). Thus,
these findings require confirmation in those of
different ages, sex, and ethnic group as well as in
nonmountaineers.
Second, combining assessments of vessel anatomy
(from color mapping) and flow velocity (from pulse
wave Doppler) allows vessel flow to be estimated.
Such calculations do, however, assume frictionless
laminar flow. Further, only maximal MCADiam is
used. True measures of flow would thus have to
integrate flow velocity with changes in vessel
diameter across the cardiac cycle. Caution should
thus be applied when interpreting absolute values.
However, we are confident about the observed trends
and relative changes. In support, the marked in-
creases in vessel diameter observed at extreme
altitude (7,950m) were rapidly reversed with supple-
mental oxygen. Further, in the high altitude study,
the ascent profile of 17 days to 5,300m was relatively
gentle and all subjects were partly acclimatized
when studied, having been at the study altitude for
1 to 3 days. The lack of increase in MCAVel we
observed is thus consistent with other studies of
MCAvelocity measured 24 to 72hours after arrival at
altitude (Ainslie et al, 2008; Brugniaux et al, 2007;
Chan et al, 2005; Van Osta et al, 2005). There was no
change in MCADiam up to 5,300m, suggesting
repeated measurements of MCADiam using this tech-
nique are reliable and repeatable.
Third, the measurements at 7,950m demonstrating
the largest increase in MCADiam were performed
within 36 to 48hours of arrival, and all subjects
had used supplementary oxygen to climb from 7,100
to 7,950m. It may be that these larger observed
changes were a more acute effect. Further
studies during exercise and with acute exposure,
both of which may accentuate the changes, are
advocated.
Although changes in relative measurements of
ultrasound and MRA-measured MCADiam correlated
well, actual values were significantly different (e.g.,
TCD diameter measurements in normoxia and
hypoxia were 5.44 and 6.28mm, while correspond-
ing MRA diameter measurements were 3.04 and
3.27mm). Such disparity has been previously re-
ported, ultrasound (both color Doppler as we used
and Power Doppler) yielding larger diameter mea-
surements than MRI (Table 4). Since our ultrasound
and MRA measurements correlate well, this implies
that although the ultrasound-measured diameter may
not be a true diameter, it reliably reflects changes in
diameter. It may be that the plane of the ultrasound,
although consistent, is not truly tangential to the
vessel and hence the crosssectional area may be more
eliptiform.
Our data imply that rSO2 decreases in the face of
increased oxygen delivery at 7,950m. An increased
delivery of deoxygenated blood would, however, not
be expected to result in an increase in regional
oxygen saturation. rSO2 measures the ratio of
oxygenated to deoxygenated blood in the interro-
gated region and does not reflect the flux of blood (or
flux of oxygen) passing through. In addition, many
other factors (such as alterations in the contribution
of arterial and venous compartments due to changes
in intravessel volume) will affect rSO2 (Wolff et al,
2007).
There have not been many studies validating TCD-
estimated changes in CBF against other measures of
cerebral perfusion. It is interesting to note that some
of the few that have attempted to correlate cerebral
perfusion, as measured using the Kety–Schmidt
technique, have found very poor correlations with
TCD velocity measurements (Nuttall et al, 1996;
Table 4 Results of various studies measuring mean MCA diameters using direct vision in cadaver studies, using MRA, angiography,
and Doppler
Measurement modality Mean MCA diameter (mm) Number of
subjects
Notes
Cadaver 2.5–4mm (mean=3.35mm) (Pai et al, 2005) 5
MRA (all 1.5T) 2.9mm (Serrador et al, 2000) 12
2.73mm (Schreiber et al, 2000) 8
2.23mm (Tarasow et al, 2007) 36
2.95mm (Hansen et al, 2007) 12
3.4mm (Valdueza et al, 1997) 6
Angiography 2.38mm (Tarasow et al, 2007) 36
Power Doppler
Proximal MCA 5.2mm 17 Subjects suspected of
Distal MCA 4.3mm (Muller et al, 2000) having vasospasm
TCCS
Proximal MCA 5.9mm 17 Subjects suspected of
Distal MCA 4.9mm (Muller et al, 2000) having vasospasm
MCA, middle cerebral artery; MRA, magnetic resonance angiography; TCCS, transcranial color-coded sonography.
The differences between MRA and Doppler-measured diameters are similar to ours.
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Weyland et al, 1994). Giller’s group investigated
further the use of TCD during exercise and con-
cluded that, because of probable vessel diameter
change, the use of TCD velocities to interpret CBF
during exercise might be invalid (Giller et al, 2000).
Our data support that caution must be used when
using TCD-measured velocity data to imply changes
in cerebral perfusion.
Possible Mechanisms of Vasodilatation
To maintain cerebral oxygen delivery in an increas-
ingly hypoxic environment, one would expect to see
an increase in CBF. This can be influenced by
alterations in vessel diameter and the velocity of
blood within it (which in turn is determined by blood
pressure and blood viscosity—Poiseuille’s law). In
this study, the first to measure both diameter and
velocity with two techniques, vasodilatation appears
to be the principal factor affecting flow. It may be that
with increasing viscosity of blood, vasodilatation
becomes the most important mechanism.
A number of mechanisms could be proposed to
underlie vasodilatation.
Hypoxia: Hypoxia-induced increases in adenosine and
nitric oxide, previously thought to mediate vasodilata-
tion at an arteriolar level, might cause arterial
vasodilatation. Other factors (such as those mediated
by hypoxia inducible factor and the cascade it induces)
are thought to occur over a longer time period (Wilson
et al, 2009). The rapid reversal of arterial dilatation
with oxygen suggests a direct hypoxic effect.
Hypocarbia: A paradoxical phenomenon of hypocar-
bic vasodilatation has previously been observed in
forced hyperventilation (Du Boulay and Symon, 1971;
Wollman et al, 1968). Du Boulay and Symon noted
vasodilatation angiographically with PaCO2 values of
20 to 25mmHg (2.6 to 3.33kPa). While such a
mechanism was not thought physiologically relevant,
the extreme hyperventilation and consequent hypo-
capnea that occurred at 7,950m (mean ETCO2=1.7 k-
Pa) might be inducing this paradoxical effect.
Implications in High Altitude Illness
The arterial oxygen content (CaO2) at rest in a
subgroup of our subjects has previously been
reported and is maintained at sea level values up to
and above 7,100m (Grocott et al, 2009). The reduc-
tion in CaO2 above that altitude coincides with the
marked MCA arterial dilatation observed. Exercise at
altitude is known to decrease CaO2 and increase
blood pressure (Imray et al, 2005). Similarly, Moller
et al (2002) reported that CaO2 was not only
maintained, but increased at rest at high altitude.
Opposite to sea level observation, CaO2 decreased
slightly at the altitude of 5,260m.
Although the increase in MCADiam only occurred
above 5,300m, a similar change may also occur at
lower altitudes as a response to acute hypoxia, or
during exercise at altitude (both of which are known
to be potential triggers for acute mountain sickness
and high altitude cerebral edema). According to
LaPlace’s law (vessel wall tension =blood pressure
 radius), the observed increase in MCADiam will
result in an increase in vessel wall tension.
The trigeminovascular system has been implicated
in the genesis of both high altitude headache and
acute mountain sickness (Jansen et al, 2000; Van Osta
et al, 2005). The observed cerebral vessel dilatation
may act as a direct mechanical trigger for this system.
Alternatively, failure to dilate might result in
increased MCA velocities and raised arterial pres-
sures in an attempt to maintain an adequate cerebral
oxygen delivery, which could also have implication
in the development of high altitude illness.
Deaths above 8,000m on Everest have been
associated with cognitive impairment, ataxia, pro-
found fatigue, late summit times, and a tendency to
fall behind (Firth et al, 2008). Our group’s recent
study with blood gas analysis at 8,400m (n=4)
demonstrated mean PaO2 was 3.28 kPa and PaCO2
was 1.77 kPa (Grocott et al, 2009). It is therefore
suggested that some climbers suffer an acute hypoxic
cerebral dysfunction and it may be that they are
reaching the limits of the adaptive mechanisms for
maintaining CaO2 and cerebral oxygen delivery.
Clinical Implications
Giller, in his editorial, ‘The Emperor has no clothes,’
challenged the long held assumption that any
changes in cerebral artery diameter that might occur
are of no significance (Giller, 2003). Other studies
have highlighted the need to obtain quantitative
measures of CBF if there is reason to suspect that the
diameter of the MCA might not remain constant, for
example, when drugs such as nitroglycerin are used
(Zuj et al, 2007).
The two studies reported here confirm that marked
cerebral hypoxia is associated with significant
increases in cerebral artery diameter. The wider
implication from this study is that any future
investigations measuring cerebral vessel blood velo-
city, must also consider potential changes in vessel
diameter. Vasospasm is known to occur following
subarachnoid hemorrhage (Gonzalez et al, 2007).
This study demonstrates that hypoxia also affects
vessel caliber. Other conditions such as sepsis,
inflammatory mediators, drugs, and alterations in
blood pH may have similar effects.
These findings offer new insights into the possible
underlying pathophysiology of acute mountain sick-
ness and high altitude cerebral edema and highlight
the importance of concurrent measurement of vessel
caliber when using Doppler velocities to infer flow.
The correlation of ultrasound measurements with
MRA measurements implies that ultrasound may
enable repeated assessments of cerebral artery size
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and flow at the bedside, during hospital transfer or in
the field (Wilson et al, 2011).
Conclusions
This is the first published field study of cerebral
perfusion above 5,500m, and the first to show that
exposure to extreme hypobaric hypoxia is associated
with an increase in MCADiam, which is rapidly
reversed by inhaled supplemental oxygen. These
field TCD findings have been replicated and con-
firmed using MRA in acute hypoxia at sea level. This
has uniquely demonstrated that ultrasound and
MRA MCA measurements correlate. The increased
diameter, as opposed to increased blood velocity, is
the major factor increasing CBF and maintaining
oxygen delivery. This may have implications for the
pathogenesis of cerebral high altitude illness and the
acclimatization process. Future studies inferring CBF
from TCD velocity measurements at altitude and
clinical studies where oxygenation may change,
must take vessel caliber into account.
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